NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)

Updated: Sep 24, 2022

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma

Drug: REGN5458

Sponsor

ClinicalTrials.gov Identifier: NCT05164250

Official Title: Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

First Posted : December 20, 2021

Click here for details on ClinicalTrials.gov

Linvoseltamab (Code C158504)

Anti-BCMA x Anti-CD3 BiTE REGN5458

Anti-BCMA/CD3 BiTE Antibody REGN5458

Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458

BiTE Antibody REGN5458

Linvoseltamab

LINVOSELTAMAB

REGN 5458

REGN-5458

REGN5458

NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM

NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM

NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM